Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03SXS
|
|||
| Former ID |
DIB005159
|
|||
| Drug Name |
LY-2875358
|
|||
| Synonyms |
C-Met mAb (cancer), Eli Lilly; Anti-c-Met antibody (cancer), Lilly
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Eli lilly
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01900652) A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Eli Lilly. | |||
| REF 3 | LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.